Bionano Genomics - BNGO Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bionano Genomics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BNGO shares.
View BNGO analyst ratings or view top-rated stocks.

2 analysts have issued 12-month price objectives for Bionano Genomics' stock. Their BNGO share price forecasts range from $7.00 to $12.00. On average, they predict the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 348.1% from the stock's current price.
View analysts price targets for BNGO or view top-rated stocks among Wall Street analysts.

Bionano Genomics' stock was trading at $2.99 at the beginning of 2022. Since then, BNGO shares have decreased by 29.1% and is now trading at $2.12.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our BNGO earnings forecast.

Bionano Genomics, Inc. (NASDAQ:BNGO) issued its quarterly earnings results on Thursday, November, 3rd. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. The firm earned $7.22 million during the quarter, compared to analyst estimates of $6.70 million. Bionano Genomics had a negative trailing twelve-month return on equity of 38.48% and a negative net margin of 451.42%.

Bionano Genomics updated its FY 2022 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.10 million-$27.60 million, compared to the consensus revenue estimate of $26.41 million.

17 employees have rated Bionano Genomics Chief Executive Officer R. Erik Holmlin on Glassdoor.com. R. Erik Holmlin has an approval rating of 73% among the company's employees. 71.0% of employees surveyed would recommend working at Bionano Genomics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionano Genomics investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Aeterna Zentaris (AEZS) and OrganiGram (OGI).

(BNGO) raised $16 million in an initial public offering (IPO) on the week of August 20th 2018. The company issued 2,500,000 shares at $6.00-$7.00 per share. Roth Capital Partners and Maxim Group served as the underwriters for the IPO and LifeSci Capital was co-manager.

Bionano Genomics trades on the NASDAQ under the ticker symbol "BNGO."

Bionano Genomics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.28%), Vanguard Group Inc. (5.30%), State Street Corp (3.19%), Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.52%), Renaissance Technologies LLC (0.47%) and Bank of New York Mellon Corp (0.45%). Insiders that own company stock include R Erik Holmlin and Yvonne Linney.
View institutional ownership trends.

Shares of BNGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNGO stock can currently be purchased for approximately $2.12.

Bionano Genomics (NASDAQ:BNGO) has a market capitalization of $629.48 million and generates $17.98 million in revenue each year. The company earns $-72,430,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis.

The company employs 299 workers across the globe.

Bionano Genomics' mailing address is 9540 TOWNE CENTRE DRIVE SUITE 100, SAN DIEGO CA, 92121. The official website for the company is www.bionanogenomics.com. The company can be reached via phone at (858) 888-7600 or via email at arr@lifesciadvisors.com.